摘要
目的探讨奈达铂联合依托泊苷(VP-16)治疗小细胞肺癌的临床疗效及不良反应的发生情况。方法选择2009年11月至2010年11月间我院收治的64例小细胞肺癌患者为研究对象,随机分为观察组和治疗组,每组32例,观察组患者给予奈达铂联合VP-16治疗,对照组患者给予顺铂联合VP-16治疗,21天为一疗程,用药两疗程后进行CT及相关检查,比较两组的临床疗效和不良反应的发生情况。结果观察组和对照组的有效率分别为78.1%和65.6%(P=0.051);中位无进展生存期分别为9.3个月和7.4个月(P>0.05);1年生存率分别为65.4%和61.2%(P>0.05)。观察组胃肠道不良反应(呕吐、恶心)的发生率显著低于对照组(P<0.05),两组间其余不良反应的发生率差异无统计学意义。结论奈达铂联合VP-16治疗小细胞肺癌疗效确切,毒副作用较轻,值得进一步推广。
Objective To investigate the therapeutic effects and adverse effects of nedaplatin plus etoposide（VP-16） on the treatment of small cell lung cancer. Methods 64 patients with small cell lung cancer who had been admitted to our hospital from November 2009 to November 2010 were selected and divided randomly into observation group and control group. Each group included 32 cases. Patients in observation group were treated with nedaplatin plus VP-16, while patients in control group were treated with cisplatin plus VP-16. One course of treatment lasted for 21 days. After treated with 2 courses, patients were examined with CT and other relative test, and the therapeutic effects and adverse effects were compared between the two groups. Results The overall response rates were 78.1% and 65.6% （P〉0.05） in the observation group and control group respectively. The median progression-free survival were respectively 9.3 months and 7.4 months （P〉0.05） respectively; 1-year survival rate were 65.4% and 61.2 % respectively （P〉0.05）. The incidences of gastrointestinal reaction （nausea and vomiting） in observation group were significantly lower than in control group（P〈0.05）. No significant difference was observed in the incidences of other adverse effects between two groups. Conclusion Nedaplatin plus VP-16 was an effective treatment regimen for small cell lung cancer.
出处
《肿瘤药学》
CAS
2012年第3期213-215,共3页
Anti-Tumor Pharmacy
关键词
奈达铂
依托泊苷
小细胞肺癌
疗效
Nedaplatin
Etoposide
Small cell lung cancer
Therapeutic effect
